New treatment method for prostate cancer patients
Researchers at the Burnet Institute in Melbourne have created a new treatment method for prostate cancer patients. The research crew, led by Pei Xiang Xing, have created a monoclonal antibody to a unique tumor marker for the treatment of prostate cancer. The monoclonal antibody is directed at cancer-producing cells carrying the specific molecule known as PIM-1, which is responsible for cell survival, proliferation and differentiation.
Prostate cancer is the third leading cause of death in men all over the world. Over 2,000 men die every year from this deadly disease, so that’s why this research is of huge importance. Prostate cancer can be compared to breast cancer in women.
“This is an exciting step in the development of new treatments for patients with prostate cancer with very promising laboratory-test results,” said Brendan Crabb, director of the Burner Institute.
Clinical trials are expected to take place in the near future.
The details are published in The Journal of Clinical Investigation.
Source: burnet.edu.au
